News Detail

Phoenix Asia signs deal to acquire ACEA Pharma for $1 billion in shares

PUBT · 1d ago

Listen to the news

Phoenix Asia signs deal to acquire ACEA Pharma for $1 billion in shares

Phoenix Asia struck a deal to buy ACEA Pharma, acquiring 100% of its shares from ACEA Therapeutics in exchange for 100,000,000 newly issued ordinary shares valued by the parties at USD 1 billion.
ACEA Pharma is a clinical-stage drug developer with programs targeting cancer, autoimmune disease, Covid-19.
Closing is expected in Q2 2026, subject to customary conditions and required approvals.
Separately, Phoenix Asia entered into a convertible promissory note for USD 20 million with controlling shareholder Phoenix Prosperity Investment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phoenix Asia Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605041615PRIMZONEFULLFEED9712672) on May 04, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.